IBAB Ion Beam Applications SA

IBA – Transparency Notification

IBA – Transparency Notification

Louvain-la-Neuve, Belgium, February 18, 2020, 17.30

Summary of the notification

IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on February 17, 2020.

In its notification, Norges Bank has notified, that following an acquisition of IBA shares with voting rights and a disposal of equivalent financial instruments, its total holding in IBA SA remains the same as in its previous notification but its holding in voting rights has crossed upwards the 3% threshold on February 14, 2020.

In details, on February 14, 2020, Norges Bank owned (A) 961.258 IBA shares with voting rights (versus 707.489 shares in its previous notification), representing 3.19 % of the total number of shares issued by IBA (30 133 920) (versus 2.35% in its previous notification), as well as (B) 447.811 equivalent financial instruments (versus 701.580 in its previous notification) representing 1.49% of the total number of shares issued by IBA (30 133 920) (versus 2.33% in its previous notification).

Content of the notification

  • Reason for the notification: Acquisition or disposal of voting securities or voting rights
  • Persons subject to the notification requirement: Norges Bank
  • Date on which the threshold is crossed: 14/02/2020
  • Threshold crossed (in %): 3%
  • Denominator: 30 133 920
  • Notified details: (extract of the received notification form)

           

A) Voting rightsPrevious notificationAfter the transaction 
 # of voting rights# of voting rights% of voting rights 
Holders of voting rights Linked to securitiesNot linked to the securitiesLinked to securitiesNot linked to the securities 
Norges Bank707.489961.258 3.19%  
 TOTAL961.25803.19%0,00% 
       
B) Equivalent financial instrumentsAfter the transaction
Holder of equivalent financial instruments Type of financial instrumentExpiration dateExercise period or date# of voting rights that may be acquired if the instrument is exercised% of voting rightsSettlement
Norges BankShares on loan (right to recall) At any time447.8111.49 %physical
 TOTAL 447.8111.49 % 
       
 TOTAL (A & B)  # of voting rights%of voting rights 
    1.409.0694,68% 
  • Full chain of controlled undertakings through which the holding is effectively held

Norges Bank is the central bank of Norway. As part of its central bank activities, Norges Bank manages Norway’s foreign exchange reserves and is responsible for management of the Norwegian Government Pension Fund Global (GPFG). The formal responsibility for management of the GPFG is placed with the Ministry of Finance, but is delegated to Norges Bank. All investments are executed by Norges Bank acting as principal and all holdings are registered in the name of Norges Bank.

For further information, please contact:

IBA

Elodie Jaumain

Paralegal

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at:

Attachment

EN
18/02/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ion Beam Applications SA

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Heineken: No respite / IBA: Attractive €15-20m acquisition in radio pharma.

Guy Sips ... (+8)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Michiel Declercq
  • Thibault Leneeuw
  • Wim Lewi

Morning Notes : BAR BB, COFB BB, FAGR BB, GLPG NA, IBAB BB, DEME BB, N...

: BAR BB, COFB BB, FAGR BB, GLPG NA, IBAB BB, DEME BB, NXFIL NA, ENRGY BB

 PRESS RELEASE

IBA acquires ORA expanding its strategic leadership in Nuclear Medicin...

IBA acquires ORA expanding its strategic leadership in Nuclear Medicine Louvain-La-Neuve, Belgium, 19 December 2025 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, acquires ORA, a global trailblazer in radiochemistry based in Belgium. This acquisition emphasizes IBA’s long-term commitment to the fast-developing and promising field of nuclear medicine. It reinforces IBA’s position at the forefront of innovation in precision oncology enabling for better diagnostic and more personalized patient...

 PRESS RELEASE

Avec l’acquisition d’ORA, IBA renforce son leadership stratégique en m...

Avec l’acquisition d’ORA, IBA renforce son leadership stratégique en médecine nucléaire Louvain-la-Neuve, Belgique, le 19 décembre 2025 - IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules et acteur de premier plan en médecine nucléaire, acquiert ORA, pionnier mondial de la radiochimie, basé en Belgique. Cette acquisition illustre l'engagement à long terme d'IBA dans le domaine en pleine expansion et à fort potentiel de la médecine nucléaire. Elle consolide la position d'IBA à l’avant-garde de l'innovation en oncologie de précision, p...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

IBA: The Lancet Journal on proton therapy new standard of care for patients with Oropharyngeal cancer. Events Calendar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch